publication date: May. 16, 2014


TGen and George Mason Form Precision Medicine Alliance

GMU President Ángel Cabrera and TGen President & Research Director Jeffrey Trent signed the memorandum of understanding to create the Molecular Medicine Alliance. Source: George Mason University/Alexis Glenn

The Translational Genomics Research Institute and George Mason University announced a strategic research alliance May 6.

Called the TGen-George Mason Molecular Medicine Alliance, the effort is designed to recommend medications and treatments to clinicians based on each patient’s molecular profile.

The alliance has submitted applications for more than $12 million in research grants for projects each organization might not have pursued on its own, the statement said.

“By combining efforts, George Mason and TGen look to develop a more precise research strategy to help people afflicted by cancer and other diseases, while pursuing additional research,” the statement said.

A non-profit genomics research institute located in Phoenix, Ariz., TGen was established by Jeffrey Trent, the founding scientific director of the National Human Genome Research Institute.

“The Molecular Medicine Alliance is an opportunity for two highly regarded institutions to integrate their complementary knowledge and human resources to help patients by using state-of-the-art technology to advance new therapeutics options,” said Jeffrey Trent, TGen president and research director.

By integrating genomics and proteomics, the alliance said it will initially focus on new treatments for metastatic breast cancer or melanoma. Research will also focus on the development of vaccines for infectious diseases, and biomarkers that can help diagnose traumatic injuries such as brain concussions.

“This is a major … Continue reading 40-20 TGen and George Mason Form Precision Medicine Alliance

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.